Cilostazol for stroke in Small Vessel Disease: Systematic Review of Current Literature

Rizaldy Taslim Pinzon


Introduction: Cerebral small vessel disease (SVD) is accounted for 25% of ischemic stroke pathology. Cilostazol is a therapeutic option for secondary ischemic stroke prevention, especially in subgroups with high risks for hemorrhagic events. The available evidences are limited for optimal management of stroke in cerebral SVD.

Objective: This systematic review aimed to identify the effectiveness of cilostazole for stroke in SVD

Method: This systematic research was done by two authors using mainly PubMed and Cochrane as a database. The terms used to search the literatures were “Cilostazol”, “Small Vessel Infarction”, “Lacunar Infarction”, “Ischemic Stroke”, and “Clinical Trial”. We measure the quality of the clinical trials using Jadad Score. If the trial manage to meet the 3 important features then the jadad score of the trial will be 3.

Results: The journal form PubMed and Cohrane was up to 3848 journals that were screened. The reviewers then begins to screening on the journals, exclude all of the irrelevant, and duplication study and make sure the inclusion and exclusion criteria were fulfilled. The result was 3 RCT studies. All studies has a good Jadad score. All of the comparison used in the studies is aspirin except for the study of Han, et al. (2014), that compare cilostazol with placebo. All of the subject that were used is above the age of 30 y.o. and the length of treatment is above 3 months. Each of the outcome in all of the RCT studies is different, but their aims is to measure the effectiveness or the efficacy of cilostazol. Huang, et al (2008) have the most subject (720 subjects) and Lee, et al (2017), have the least subject (80 subjects).


Key words: cilostazol, stroke, small vessel disease


  • There are currently no refbacks.

Creative Commons License
This work is licensed under a Creative Commons Attribution 4.0 International License.